Invesco Markets plc NASDAQ Biotech UCITS ETF (SBIO)
No change
- Add to watchlist
- Create an alert
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
n/a
n/a
$51.30
London
$45.20
n/a
$41.55
$319.56M
$0.41 (0.92%) Previous:
$0.41
n/a
n/a
USD
ETP Basics
| Issuer: | Invesco Markets plc |
|---|---|
| Structure: | ETF |
| Replication method: | Swaps |
| Securities lending: | No |
| Number of holdings: | 212 |
| Size: | $319.6M |
| Launch date: | 07 November 2014 |
| Launch price: | $30.84 |
| UCITS: | Yes |
| Reporting status: | Yes |
| Domicile: | Ireland |
| Complex product: | Non-complex |
| ISIN: | IE00BQ70R696 |
Annual & interim reports
Before you invest, please make sure you read the documents below
Ready to invest?
Important Documents
There are no documents available for this stock.
OBJECTIVE
| Index: | The NASDAQ Biotechnology Index Total Return provides exposure to biotechnology and pharmaceuticals companies (as defined by Industry Classification Benchmark) listed on the NASDAQ Stock Market. Stocks are filtered to meet minimum market capitalisation and liquidity requirements. They are then weighted by modified market capitalisation: • The largest five constituents are capped at 8% • Remaining constituents are capped at 4% • The index is rebalanced quarterly and reviewed annually |
|---|---|
| Aim: |
The Invesco NASDAQ Biotech UCITS ETF aims to provide the performance of the NASDAQ...
Read full aim for Invesco Markets plc |
| Leverage: | 100% |
| Currency hedging: | n/a |
COSTS
| Ongoing Charge (OCF/TER): | 0.40% |
|---|---|
| Management fee: | 0.40% |
| Indicative spread: | 0.18% |
In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.
Performance
| 1 week 1W | 2.86% | 1 year 1Y | 3.76% |
|---|---|---|---|
| 1 month 1M | 3.69% | 2 years 2Y | 2.44% |
| 3 months 3M | 8.14% | 3 years 3Y | 8.59% |
| 6 months 6M | 6.01% | 5 years 5Y | 15% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
| Security | Weight |
|---|---|
| GILEAD SCIENCES | 9.85% |
| VERTEX PHARMACEUTICALS INC | 7.89% |
| AMGEN | 7.06% |
| REGENERON PHARMACEUTICALS INC | 5.36% |
| ASTRAZENECA | 3.99% |
| ALNYLAM PHARMACEUTICALS | 3.32% |
| BIOGEN | 2.38% |
| ILLUMINA | 2.35% |
| ARGENX SE | 2.01% |
| UNITED THERAPEUTICS CORPORATION | 1.72% |
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.